ArticleFrontiers in oncology2023
Cost-effectiveness analysis of toripalimab for metastatic or recurrent triple-negative breast cancer.
Jiangbo Shao et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it